ID   GALT2_HUMAN             Reviewed;         571 AA.
AC   Q10471; A8K1Y3; B7Z8V8; C5HU00; Q9NPY4;
DT   16-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   03-AUG-2022, entry version 196.
DE   RecName: Full=Polypeptide N-acetylgalactosaminyltransferase 2;
DE            EC=2.4.1.41 {ECO:0000269|PubMed:16434399, ECO:0000269|PubMed:25939779, ECO:0000269|PubMed:7592619};
DE   AltName: Full=Polypeptide GalNAc transferase 2;
DE            Short=GalNAc-T2;
DE            Short=pp-GaNTase 2;
DE   AltName: Full=Protein-UDP acetylgalactosaminyltransferase 2;
DE   AltName: Full=UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 2;
DE   Contains:
DE     RecName: Full=Polypeptide N-acetylgalactosaminyltransferase 2 soluble form;
GN   Name=GALNT2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 52-93; 104-120;
RP   170-182; 193-218; 303-323; 421-424 AND 510-546, FUNCTION, COFACTOR,
RP   CATALYTIC ACTIVITY, PATHWAY, AND TISSUE SPECIFICITY.
RC   TISSUE=Gastric carcinoma;
RX   PubMed=7592619; DOI=10.1074/jbc.270.41.24166;
RA   White T., Bennett E.P., Takio K., Soerensen T., Bonding N., Clausen H.;
RT   "Purification and cDNA cloning of a human UDP-N-acetyl-alpha-D-
RT   galactosamine:polypeptide N-acetylgalactosaminyltransferase.";
RL   J. Biol. Chem. 270:24156-24165(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   MET-554.
RC   TISSUE=Hippocampus, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION.
RX   PubMed=9295285; DOI=10.1074/jbc.272.38.23503;
RA   Wandall H.H., Hassan H., Mirgorodskaya E., Kristensen A.K., Roepstorff P.,
RA   Bennett E.P., Nielsen P.A., Hollingsworth M.A., Burchell J.,
RA   Taylor-Papadimitriou J., Clausen H.;
RT   "Substrate specificities of three members of the human UDP-N-acetyl-alpha-
RT   D-galactosamine:polypeptide N-acetylgalactosaminyltransferase family,
RT   GalNAc-T1, -T2, and -T3.";
RL   J. Biol. Chem. 272:23503-23514(1997).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9394011; DOI=10.1242/jcs.111.1.45;
RA   Roettger S., White J., Wandall H.H., Olivo J.-C., Stark A., Bennett E.P.,
RA   Whitehouse C., Berger E.G., Clausen H., Nilsson T.;
RT   "Localization of three human polypeptide GalNAc-transferases in HeLa cells
RT   suggests initiation of O-linked glycosylation throughout the Golgi
RT   apparatus.";
RL   J. Cell Sci. 111:45-60(1998).
RN   [9]
RP   FUNCTION.
RX   PubMed=12438318; DOI=10.1074/jbc.m211097200;
RA   Iwasaki H., Zhang Y., Tachibana K., Gotoh M., Kikuchi N., Kwon Y.-D.,
RA   Togayachi A., Kudo T., Kubota T., Narimatsu H.;
RT   "Initiation of O-glycan synthesis in IgA1 hinge region is determined by a
RT   single enzyme, UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
RT   acetylgalactosaminyltransferase 2.";
RL   J. Biol. Chem. 278:5613-5621(2003).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-536, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.64 ANGSTROMS) OF 75-571 IN COMPLEX WITH UDP;
RP   PEPTIDE SUBSTRATE AND MANGANESE, FUNCTION, CATALYTIC ACTIVITY, COFACTOR,
RP   PATHWAY, AND DISULFIDE BONDS.
RX   PubMed=16434399; DOI=10.1074/jbc.m513590200;
RA   Fritz T.A., Raman J., Tabak L.A.;
RT   "Dynamic association between the catalytic and lectin domains of human UDP-
RT   GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase-2.";
RL   J. Biol. Chem. 281:8613-8619(2006).
RN   [15] {ECO:0007744|PDB:4D0T, ECO:0007744|PDB:4D0Z, ECO:0007744|PDB:4D11}
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) IN COMPLEXES WITH SUBSTRATE ANALOGS
RP   AND MANGANESE, COFACTOR, AND DISULFIDE BONDS.
RX   PubMed=24954443; DOI=10.1002/anie.201402781;
RA   Lira-Navarrete E., Iglesias-Fernandez J., Zandberg W.F., Companon I.,
RA   Kong Y., Corzana F., Pinto B.M., Clausen H., Peregrina J.M., Vocadlo D.J.,
RA   Rovira C., Hurtado-Guerrero R.;
RT   "Substrate-guided front-face reaction revealed by combined structural
RT   snapshots and metadynamics for the polypeptide N-
RT   acetylgalactosaminyltransferase2.";
RL   Angew. Chem. Int. Ed. Engl. 53:8206-8210(2014).
RN   [16] {ECO:0007744|PDB:5AJN, ECO:0007744|PDB:5AJO, ECO:0007744|PDB:5AJP}
RP   X-RAY CRYSTALLOGRAPHY (1.48 ANGSTROMS) IN COMPLEXES WITH MANGANESE AND
RP   SUBSTRATES, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, PATHWAY, MUTAGENESIS OF
RP   TRP-282 AND PHE-361, AND DISULFIDE BONDS.
RX   PubMed=25939779; DOI=10.1038/ncomms7937;
RA   Lira-Navarrete E., de Las Rivas M., Companon I., Pallares M.C., Kong Y.,
RA   Iglesias-Fernandez J., Bernardes G.J., Peregrina J.M., Rovira C.,
RA   Bernado P., Bruscolini P., Clausen H., Lostao A., Corzana F.,
RA   Hurtado-Guerrero R.;
RT   "Dynamic interplay between catalytic and lectin domains of GalNAc-
RT   transferases modulates protein O-glycosylation.";
RL   Nat. Commun. 6:6937-6937(2015).
RN   [17]
RP   VARIANTS CDG2T SER-104 AND 289-GLN--GLN-571 DEL, CHARACTERIZATION OF
RP   VARIANTS CDG2T SER-104 AND 289-GLN--GLN-571 DEL, INVOLVEMENT IN CDG2T, AND
RP   FUNCTION.
RX   PubMed=27508872; DOI=10.1016/j.cmet.2016.07.012;
RG   Myocardial Infarction Exome Sequencing Study;
RA   Khetarpal S.A., Schjoldager K.T., Christoffersen C., Raghavan A.,
RA   Edmondson A.C., Reutter H.M., Ahmed B., Ouazzani R., Peloso G.M.,
RA   Vitali C., Zhao W., Somasundara A.V., Millar J.S., Park Y., Fernando G.,
RA   Livanov V., Choi S., Noe E., Patel P., Ho S.P., Kirchgessner T.G.,
RA   Wandall H.H., Hansen L., Bennett E.P., Vakhrushev S.Y., Saleheen D.,
RA   Kathiresan S., Brown C.D., Abou Jamra R., LeGuern E., Clausen H.,
RA   Rader D.J.;
RT   "Loss of function of GALNT2 lowers high-density lipoproteins in humans,
RT   nonhuman primates, and rodents.";
RL   Cell Metab. 24:234-245(2016).
RN   [18]
RP   VARIANTS CDG2T 200-ARG--GLN-571 DEL; PRO-210 AND 289-GLN--GLN-571 DEL,
RP   CHARACTERIZATION OF VARIANTS CDG2T 200-ARG--GLN-571 DEL; PRO-210 AND
RP   289-GLN--GLN-571 DEL, VARIANTS ARG-271 AND VAL-493, CHARACTERIZATION OF
RP   VARIANTS ARG-271 AND VAL-493, AND FUNCTION.
RX   PubMed=32293671; DOI=10.1093/brain/awaa063;
RA   Zilmer M., Edmondson A.C., Khetarpal S.A., Alesi V., Zaki M.S., Rostasy K.,
RA   Madsen C.G., Lepri F.R., Sinibaldi L., Cusmai R., Novelli A., Issa M.Y.,
RA   Fenger C.D., Abou Jamra R., Reutter H., Briuglia S., Agolini E., Hansen L.,
RA   Petaejae-Repo U.E., Hintze J., Raymond K.M., Liedtke K., Stanley V.,
RA   Musaev D., Gleeson J.G., Vitali C., O'Brien W.T., Gardella E., Rubboli G.,
RA   Rader D.J., Schjoldager K.T., Moeller R.S.;
RT   "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss
RT   of function.";
RL   Brain 143:1114-1126(2020).
CC   -!- FUNCTION: Catalyzes the initial reaction in O-linked oligosaccharide
CC       biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a
CC       serine or threonine residue on the protein receptor. Has a broad
CC       spectrum of substrates for peptides such as EA2, Muc5AC, Muc1a, Muc1b.
CC       Probably involved in O-linked glycosylation of the immunoglobulin A1
CC       (IgA1) hinge region. Involved in O-linked glycosylation of APOC-III,
CC       ANGPTL3 and PLTP. It participates in the regulation of HDL-C metabolism
CC       (PubMed:27508872, PubMed:32293671). {ECO:0000269|PubMed:12438318,
CC       ECO:0000269|PubMed:16434399, ECO:0000269|PubMed:25939779,
CC       ECO:0000269|PubMed:27508872, ECO:0000269|PubMed:32293671,
CC       ECO:0000269|PubMed:7592619, ECO:0000269|PubMed:9295285}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-seryl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = 3-O-
CC         [N-acetyl-alpha-D-galactosaminyl]-L-seryl-[protein] + H(+) + UDP;
CC         Xref=Rhea:RHEA:23956, Rhea:RHEA-COMP:9863, Rhea:RHEA-COMP:12788,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:53604,
CC         ChEBI:CHEBI:58223, ChEBI:CHEBI:67138; EC=2.4.1.41;
CC         Evidence={ECO:0000269|PubMed:16434399, ECO:0000269|PubMed:25939779,
CC         ECO:0000269|PubMed:7592619};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-threonyl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = 3-
CC         O-[N-acetyl-alpha-D-galactosaminyl]-L-threonyl-[protein] + H(+) +
CC         UDP; Xref=Rhea:RHEA:52424, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11689, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:58223,
CC         ChEBI:CHEBI:67138, ChEBI:CHEBI:87075; EC=2.4.1.41;
CC         Evidence={ECO:0000269|PubMed:16434399, ECO:0000269|PubMed:25939779,
CC         ECO:0000269|PubMed:7592619};
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:16434399, ECO:0000269|PubMed:24954443,
CC         ECO:0000269|PubMed:25939779, ECO:0000269|PubMed:7592619};
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC       {ECO:0000269|PubMed:16434399, ECO:0000269|PubMed:25939779,
CC       ECO:0000269|PubMed:7592619}.
CC   -!- INTERACTION:
CC       Q10471; Q9BXK5: BCL2L13; NbExp=3; IntAct=EBI-10226985, EBI-747430;
CC       Q10471; O75208: COQ9; NbExp=3; IntAct=EBI-10226985, EBI-724524;
CC       Q10471; Q8N6L0: KASH5; NbExp=8; IntAct=EBI-10226985, EBI-749265;
CC       Q10471; Q9HC36: MRM3; NbExp=3; IntAct=EBI-10226985, EBI-1045440;
CC       Q10471; Q9HC29: NOD2; NbExp=2; IntAct=EBI-10226985, EBI-7445625;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, Golgi stack membrane
CC       {ECO:0000269|PubMed:9394011}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:9394011}. Secreted {ECO:0000269|PubMed:9394011}.
CC       Note=Resides preferentially in the trans and medial parts of the Golgi
CC       stack. A secreted form also exists.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q10471-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q10471-2; Sequence=VSP_056491, VSP_056492, VSP_056493;
CC   -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:7592619}.
CC   -!- DOMAIN: There are two conserved domains in the glycosyltransferase
CC       region: the N-terminal domain (domain A, also called GT1 motif), which
CC       is probably involved in manganese coordination and substrate binding
CC       and the C-terminal domain (domain B, also called Gal/GalNAc-T motif),
CC       which is probably involved in catalytic reaction and UDP-Gal binding.
CC       {ECO:0000250}.
CC   -!- DOMAIN: The ricin B-type lectin domain binds to GalNAc and contributes
CC       to the glycopeptide specificity. {ECO:0000250}.
CC   -!- DISEASE: Congenital disorder of glycosylation 2T (CDG2T) [MIM:618885]:
CC       A form of congenital disorder of glycosylation, a genetically
CC       heterogeneous group of multisystem disorders caused by a defect in
CC       glycoprotein biosynthesis and characterized by under-glycosylated serum
CC       glycoproteins. Congenital disorders of glycosylation result in a wide
CC       variety of clinical features, such as defects in the nervous system
CC       development, psychomotor retardation, dysmorphic features, hypotonia,
CC       coagulation disorders, and immunodeficiency. The broad spectrum of
CC       features reflects the critical role of N-glycoproteins during embryonic
CC       development, differentiation, and maintenance of cell functions. CDG2T
CC       is an autosomal recessive form characterized by global developmental
CC       delay, intellectual disability with language deficit, autistic
CC       features, behavioral abnormalities, epilepsy, chronic insomnia, white
CC       matter changes on brain imaging, dysmorphic features, decreased
CC       stature, and decreased high density lipoprotein cholesterol levels.
CC       {ECO:0000269|PubMed:27508872, ECO:0000269|PubMed:32293671}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 2 family. GalNAc-T
CC       subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - GTase;
CC       Note=Polypeptide N-acetylgalactosaminyltransferase 2;
CC       URL="http://www.functionalglycomics.org/glycomics/molecule/jsp/glycoEnzyme/viewGlycoEnzyme.jsp?gbpId=gt_hum_484";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X85019; CAA59381.1; -; mRNA.
DR   EMBL; AK290048; BAF82737.1; -; mRNA.
DR   EMBL; AK304029; BAH14094.1; -; mRNA.
DR   EMBL; AL592228; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL078646; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL117349; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL136988; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; FJ515852; ACS13744.1; -; Genomic_DNA.
DR   EMBL; CH471098; EAW69911.1; -; Genomic_DNA.
DR   EMBL; BC041120; AAH41120.1; -; mRNA.
DR   CCDS; CCDS1582.1; -. [Q10471-1]
DR   PIR; I37405; I37405.
DR   RefSeq; NP_001278795.1; NM_001291866.1.
DR   RefSeq; NP_004472.1; NM_004481.4. [Q10471-1]
DR   PDB; 2FFU; X-ray; 1.64 A; A=75-571.
DR   PDB; 2FFV; X-ray; 2.75 A; A/B=75-571.
DR   PDB; 4D0T; X-ray; 2.45 A; A/B/C/D/E/F=1-571.
DR   PDB; 4D0Z; X-ray; 2.20 A; A/B/C/D/E/F=1-571.
DR   PDB; 4D11; X-ray; 2.85 A; A/B/C/D/E/F=1-571.
DR   PDB; 5AJN; X-ray; 1.67 A; A=1-571.
DR   PDB; 5AJO; X-ray; 1.48 A; A=1-571.
DR   PDB; 5AJP; X-ray; 1.65 A; A=1-571.
DR   PDB; 5FV9; X-ray; 2.07 A; A/B/C/D/E/F=1-571.
DR   PDB; 5NDF; X-ray; 2.30 A; A/B/C/D/E/F=1-571.
DR   PDB; 6E7I; X-ray; 1.80 A; A=74-571.
DR   PDB; 6EGS; X-ray; 2.70 A; A/B=75-571.
DR   PDB; 6NQT; X-ray; 3.05 A; A/B/C/D/E/F=1-571.
DR   PDBsum; 2FFU; -.
DR   PDBsum; 2FFV; -.
DR   PDBsum; 4D0T; -.
DR   PDBsum; 4D0Z; -.
DR   PDBsum; 4D11; -.
DR   PDBsum; 5AJN; -.
DR   PDBsum; 5AJO; -.
DR   PDBsum; 5AJP; -.
DR   PDBsum; 5FV9; -.
DR   PDBsum; 5NDF; -.
DR   PDBsum; 6E7I; -.
DR   PDBsum; 6EGS; -.
DR   PDBsum; 6NQT; -.
DR   AlphaFoldDB; Q10471; -.
DR   SMR; Q10471; -.
DR   BioGRID; 108862; 105.
DR   IntAct; Q10471; 29.
DR   MINT; Q10471; -.
DR   STRING; 9606.ENSP00000355632; -.
DR   BindingDB; Q10471; -.
DR   ChEMBL; CHEMBL3713355; -.
DR   CAZy; CBM13; Carbohydrate-Binding Module Family 13.
DR   CAZy; GT27; Glycosyltransferase Family 27.
DR   UniLectin; Q10471; -.
DR   GlyGen; Q10471; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q10471; -.
DR   PhosphoSitePlus; Q10471; -.
DR   SwissPalm; Q10471; -.
DR   BioMuta; GALNT2; -.
DR   DMDM; 51315838; -.
DR   EPD; Q10471; -.
DR   jPOST; Q10471; -.
DR   MassIVE; Q10471; -.
DR   MaxQB; Q10471; -.
DR   PaxDb; Q10471; -.
DR   PeptideAtlas; Q10471; -.
DR   PRIDE; Q10471; -.
DR   ProteomicsDB; 58854; -. [Q10471-1]
DR   ProteomicsDB; 6986; -.
DR   Antibodypedia; 2493; 177 antibodies from 28 providers.
DR   DNASU; 2590; -.
DR   Ensembl; ENST00000366672.5; ENSP00000355632.4; ENSG00000143641.10. [Q10471-1]
DR   GeneID; 2590; -.
DR   KEGG; hsa:2590; -.
DR   MANE-Select; ENST00000366672.5; ENSP00000355632.4; NM_004481.5; NP_004472.1.
DR   UCSC; uc010pwa.2; human. [Q10471-1]
DR   CTD; 2590; -.
DR   DisGeNET; 2590; -.
DR   GeneCards; GALNT2; -.
DR   HGNC; HGNC:4124; GALNT2.
DR   HPA; ENSG00000143641; Low tissue specificity.
DR   MalaCards; GALNT2; -.
DR   MIM; 602274; gene.
DR   MIM; 618885; phenotype.
DR   neXtProt; NX_Q10471; -.
DR   OpenTargets; ENSG00000143641; -.
DR   PharmGKB; PA28537; -.
DR   VEuPathDB; HostDB:ENSG00000143641; -.
DR   eggNOG; KOG3738; Eukaryota.
DR   GeneTree; ENSGT00940000156958; -.
DR   HOGENOM; CLU_013477_0_2_1; -.
DR   InParanoid; Q10471; -.
DR   OMA; QEWAFSK; -.
DR   OrthoDB; 606683at2759; -.
DR   PhylomeDB; Q10471; -.
DR   TreeFam; TF313267; -.
DR   BRENDA; 2.4.1.41; 2681.
DR   PathwayCommons; Q10471; -.
DR   Reactome; R-HSA-6811436; COPI-independent Golgi-to-ER retrograde traffic.
DR   Reactome; R-HSA-913709; O-linked glycosylation of mucins.
DR   SignaLink; Q10471; -.
DR   UniPathway; UPA00378; -.
DR   BioGRID-ORCS; 2590; 16 hits in 1084 CRISPR screens.
DR   ChiTaRS; GALNT2; human.
DR   EvolutionaryTrace; Q10471; -.
DR   GeneWiki; GALNT2; -.
DR   GenomeRNAi; 2590; -.
DR   Pharos; Q10471; Tchem.
DR   PRO; PR:Q10471; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q10471; protein.
DR   Bgee; ENSG00000143641; Expressed in descending thoracic aorta and 195 other tissues.
DR   ExpressionAtlas; Q10471; baseline and differential.
DR   Genevisible; Q10471; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:BHF-UCL.
DR   GO; GO:0032580; C:Golgi cisterna membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005795; C:Golgi stack; IDA:BHF-UCL.
DR   GO; GO:0030173; C:integral component of Golgi membrane; NAS:BHF-UCL.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0004653; F:polypeptide N-acetylgalactosaminyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0016266; P:O-glycan processing; IDA:GO_Central.
DR   GO; GO:0051604; P:protein maturation; IDA:BHF-UCL.
DR   GO; GO:0006493; P:protein O-linked glycosylation; IDA:UniProtKB.
DR   GO; GO:0018242; P:protein O-linked glycosylation via serine; IDA:BHF-UCL.
DR   GO; GO:0018243; P:protein O-linked glycosylation via threonine; IDA:BHF-UCL.
DR   CDD; cd02510; pp-GalNAc-T; 1.
DR   CDD; cd00161; RICIN; 1.
DR   Gene3D; 3.90.550.10; -; 1.
DR   InterPro; IPR045885; GalNAc-T.
DR   InterPro; IPR001173; Glyco_trans_2-like.
DR   InterPro; IPR029044; Nucleotide-diphossugar_trans.
DR   InterPro; IPR035992; Ricin_B-like_lectins.
DR   InterPro; IPR000772; Ricin_B_lectin.
DR   Pfam; PF00535; Glycos_transf_2; 1.
DR   Pfam; PF00652; Ricin_B_lectin; 1.
DR   SMART; SM00458; RICIN; 1.
DR   SUPFAM; SSF50370; SSF50370; 1.
DR   SUPFAM; SSF53448; SSF53448; 1.
DR   PROSITE; PS50231; RICIN_B_LECTIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Congenital disorder of glycosylation;
KW   Direct protein sequencing; Disease variant; Disulfide bond;
KW   Glycosyltransferase; Golgi apparatus; Lectin; Manganese; Membrane;
KW   Metal-binding; Phosphoprotein; Reference proteome; Secreted; Signal-anchor;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN           1..571
FT                   /note="Polypeptide N-acetylgalactosaminyltransferase 2"
FT                   /id="PRO_0000223391"
FT   CHAIN           52..571
FT                   /note="Polypeptide N-acetylgalactosaminyltransferase 2
FT                   soluble form"
FT                   /id="PRO_0000012265"
FT   TOPO_DOM        1..6
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        7..24
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        25..571
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          443..566
FT                   /note="Ricin B-type lectin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174"
FT   REGION          53..74
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          135..240
FT                   /note="Catalytic subdomain A"
FT   REGION          300..362
FT                   /note="Catalytic subdomain B"
FT   BINDING         143
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:16434399,
FT                   ECO:0000269|PubMed:24954443, ECO:0000269|PubMed:25939779,
FT                   ECO:0007744|PDB:2FFU, ECO:0007744|PDB:2FFV,
FT                   ECO:0007744|PDB:4D0T, ECO:0007744|PDB:4D11,
FT                   ECO:0007744|PDB:5AJP, ECO:0007744|PDB:5FV9"
FT   BINDING         176
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:16434399,
FT                   ECO:0000269|PubMed:24954443, ECO:0000269|PubMed:25939779,
FT                   ECO:0007744|PDB:2FFU, ECO:0007744|PDB:2FFV,
FT                   ECO:0007744|PDB:4D0T, ECO:0007744|PDB:4D11,
FT                   ECO:0007744|PDB:5AJP, ECO:0007744|PDB:5FV9"
FT   BINDING         201
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:16434399,
FT                   ECO:0000269|PubMed:24954443, ECO:0000269|PubMed:25939779,
FT                   ECO:0007744|PDB:2FFU, ECO:0007744|PDB:2FFV,
FT                   ECO:0007744|PDB:4D0T, ECO:0007744|PDB:4D11,
FT                   ECO:0007744|PDB:5AJP, ECO:0007744|PDB:5FV9"
FT   BINDING         224
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000269|PubMed:16434399,
FT                   ECO:0000269|PubMed:24954443, ECO:0000269|PubMed:25939779,
FT                   ECO:0007744|PDB:2FFU, ECO:0007744|PDB:2FFV,
FT                   ECO:0007744|PDB:4D0T, ECO:0007744|PDB:4D0Z,
FT                   ECO:0007744|PDB:4D11, ECO:0007744|PDB:5AJP,
FT                   ECO:0007744|PDB:5FV9"
FT   BINDING         225
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:16434399,
FT                   ECO:0000269|PubMed:24954443, ECO:0000269|PubMed:25939779,
FT                   ECO:0007744|PDB:2FFU, ECO:0007744|PDB:2FFV,
FT                   ECO:0007744|PDB:4D0T, ECO:0007744|PDB:4D11,
FT                   ECO:0007744|PDB:5AJP, ECO:0007744|PDB:5FV9"
FT   BINDING         226
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000269|PubMed:16434399,
FT                   ECO:0000269|PubMed:24954443, ECO:0000269|PubMed:25939779,
FT                   ECO:0007744|PDB:2FFU, ECO:0007744|PDB:2FFV,
FT                   ECO:0007744|PDB:4D0T, ECO:0007744|PDB:4D0Z,
FT                   ECO:0007744|PDB:4D11, ECO:0007744|PDB:5AJP,
FT                   ECO:0007744|PDB:5FV9"
FT   BINDING         331
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:16434399,
FT                   ECO:0000269|PubMed:24954443, ECO:0000269|PubMed:25939779,
FT                   ECO:0007744|PDB:2FFU, ECO:0007744|PDB:2FFV,
FT                   ECO:0007744|PDB:4D0T, ECO:0007744|PDB:4D11,
FT                   ECO:0007744|PDB:5AJP, ECO:0007744|PDB:5FV9"
FT   BINDING         359
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000269|PubMed:16434399,
FT                   ECO:0000269|PubMed:24954443, ECO:0000269|PubMed:25939779,
FT                   ECO:0007744|PDB:2FFU, ECO:0007744|PDB:2FFV,
FT                   ECO:0007744|PDB:4D0T, ECO:0007744|PDB:4D0Z,
FT                   ECO:0007744|PDB:4D11, ECO:0007744|PDB:5AJP,
FT                   ECO:0007744|PDB:5FV9"
FT   BINDING         362
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:16434399,
FT                   ECO:0000269|PubMed:24954443, ECO:0000269|PubMed:25939779,
FT                   ECO:0007744|PDB:2FFU, ECO:0007744|PDB:2FFV,
FT                   ECO:0007744|PDB:4D0T, ECO:0007744|PDB:4D11,
FT                   ECO:0007744|PDB:5AJP, ECO:0007744|PDB:5FV9"
FT   BINDING         365
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:16434399,
FT                   ECO:0000269|PubMed:24954443, ECO:0000269|PubMed:25939779,
FT                   ECO:0007744|PDB:2FFU, ECO:0007744|PDB:2FFV,
FT                   ECO:0007744|PDB:4D0T, ECO:0007744|PDB:4D11,
FT                   ECO:0007744|PDB:5AJP, ECO:0007744|PDB:5FV9"
FT   BINDING         367
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:16434399,
FT                   ECO:0000269|PubMed:24954443, ECO:0000269|PubMed:25939779,
FT                   ECO:0007744|PDB:2FFU, ECO:0007744|PDB:2FFV,
FT                   ECO:0007744|PDB:4D0T, ECO:0007744|PDB:4D0Z,
FT                   ECO:0007744|PDB:4D11, ECO:0007744|PDB:5AJN,
FT                   ECO:0007744|PDB:5AJO, ECO:0007744|PDB:5AJP,
FT                   ECO:0007744|PDB:5FV9, ECO:0007744|PDB:5NDF,
FT                   ECO:0007744|PDB:6EGS"
FT   SITE            516
FT                   /note="Not glycosylated"
FT   MOD_RES         536
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   DISULFID        126..354
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:16434399, ECO:0000269|PubMed:24954443,
FT                   ECO:0000269|PubMed:25939779, ECO:0007744|PDB:2FFU,
FT                   ECO:0007744|PDB:2FFV, ECO:0007744|PDB:4D0T,
FT                   ECO:0007744|PDB:4D0Z, ECO:0007744|PDB:4D11,
FT                   ECO:0007744|PDB:5AJN, ECO:0007744|PDB:5AJO,
FT                   ECO:0007744|PDB:5AJP, ECO:0007744|PDB:5FV9,
FT                   ECO:0007744|PDB:5NDF, ECO:0007744|PDB:6EGS"
FT   DISULFID        345..423
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:16434399, ECO:0000269|PubMed:24954443,
FT                   ECO:0000269|PubMed:25939779, ECO:0007744|PDB:2FFU,
FT                   ECO:0007744|PDB:2FFV, ECO:0007744|PDB:4D0T,
FT                   ECO:0007744|PDB:4D0Z, ECO:0007744|PDB:4D11,
FT                   ECO:0007744|PDB:5AJN, ECO:0007744|PDB:5AJO,
FT                   ECO:0007744|PDB:5AJP, ECO:0007744|PDB:5FV9,
FT                   ECO:0007744|PDB:5NDF, ECO:0007744|PDB:6EGS"
FT   DISULFID        456..473
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:16434399, ECO:0000269|PubMed:24954443,
FT                   ECO:0000269|PubMed:25939779, ECO:0007744|PDB:2FFU,
FT                   ECO:0007744|PDB:2FFV, ECO:0007744|PDB:4D0T,
FT                   ECO:0007744|PDB:4D0Z, ECO:0007744|PDB:4D11,
FT                   ECO:0007744|PDB:5AJN, ECO:0007744|PDB:5AJO,
FT                   ECO:0007744|PDB:5AJP, ECO:0007744|PDB:5FV9,
FT                   ECO:0007744|PDB:5NDF, ECO:0007744|PDB:6EGS"
FT   DISULFID        496..513
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:16434399, ECO:0000269|PubMed:24954443,
FT                   ECO:0000269|PubMed:25939779, ECO:0007744|PDB:2FFU,
FT                   ECO:0007744|PDB:2FFV, ECO:0007744|PDB:4D0T,
FT                   ECO:0007744|PDB:4D0Z, ECO:0007744|PDB:4D11,
FT                   ECO:0007744|PDB:5AJN, ECO:0007744|PDB:5AJO,
FT                   ECO:0007744|PDB:5AJP, ECO:0007744|PDB:5FV9,
FT                   ECO:0007744|PDB:5NDF, ECO:0007744|PDB:6EGS"
FT   DISULFID        539..555
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:16434399, ECO:0000269|PubMed:24954443,
FT                   ECO:0000269|PubMed:25939779, ECO:0007744|PDB:2FFU,
FT                   ECO:0007744|PDB:2FFV, ECO:0007744|PDB:4D0T,
FT                   ECO:0007744|PDB:4D0Z, ECO:0007744|PDB:4D11,
FT                   ECO:0007744|PDB:5AJN, ECO:0007744|PDB:5AJO,
FT                   ECO:0007744|PDB:5AJP, ECO:0007744|PDB:5FV9,
FT                   ECO:0007744|PDB:5NDF, ECO:0007744|PDB:6EGS"
FT   VAR_SEQ         1..90
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056491"
FT   VAR_SEQ         303..355
FT                   /note="TPMIAGGLFVMDKFYFEELGKYDMMMDVWGGENLEISFRVWQCGGSLEIIPC
FT                   S -> DLVPRVAVWWQPGDHPVQPCGTRVPEAAPLHVPGWQWHCLCPKHPPGSRGLDG
FT                   (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056492"
FT   VAR_SEQ         356..571
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056493"
FT   VARIANT         104
FT                   /note="F -> S (in CDG2T; loss-of-funtion variant resulting
FT                   in lack of ApoC-III and IgA1 glycosylation)"
FT                   /evidence="ECO:0000269|PubMed:27508872"
FT                   /id="VAR_084283"
FT   VARIANT         200..571
FT                   /note="Missing (in CDG2T; loss of ApoC-III glycosylation)"
FT                   /evidence="ECO:0000269|PubMed:32293671"
FT                   /id="VAR_084284"
FT   VARIANT         210
FT                   /note="R -> P (in CDG2T; loss of ApoC-III glycosylation)"
FT                   /evidence="ECO:0000269|PubMed:32293671"
FT                   /id="VAR_084285"
FT   VARIANT         245
FT                   /note="R -> H (in dbSNP:rs1923950)"
FT                   /id="VAR_049240"
FT   VARIANT         271
FT                   /note="K -> R (likely benign variant; does not affect
FT                   ApoC-III glycosylation)"
FT                   /evidence="ECO:0000269|PubMed:32293671"
FT                   /id="VAR_084286"
FT   VARIANT         289..571
FT                   /note="Missing (in CDG2T; loss-of-funtion variant resulting
FT                   in lack of ApoC-III glycosylation; b)"
FT                   /evidence="ECO:0000269|PubMed:27508872,
FT                   ECO:0000269|PubMed:32293671"
FT                   /id="VAR_084287"
FT   VARIANT         493
FT                   /note="M -> V (likely benign variant; does not affect
FT                   ApoC-III glycosylation; dbSNP:rs774570005)"
FT                   /evidence="ECO:0000269|PubMed:32293671"
FT                   /id="VAR_084288"
FT   VARIANT         554
FT                   /note="V -> M (in dbSNP:rs2273970)"
FT                   /evidence="ECO:0000269|PubMed:14702039"
FT                   /id="VAR_019575"
FT   MUTAGEN         282
FT                   /note="W->A: Loss of enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:25939779"
FT   MUTAGEN         361
FT                   /note="F->A: Loss of enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:25939779"
FT   CONFLICT        70
FT                   /note="T -> G (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        78
FT                   /note="W -> D (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        93
FT                   /note="R -> G (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        210
FT                   /note="R -> W (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        290..291
FT                   /note="RR -> SC (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        293
FT                   /note="R -> Q (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        300
FT                   /note="P -> H (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        522
FT                   /note="W -> A (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        533
FT                   /note="H -> M (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   HELIX           78..80
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           83..87
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           88..90
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   TURN            98..102
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           106..111
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           124..128
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          138..146
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           149..162
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           165..167
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          168..175
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           182..185
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           186..189
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          193..197
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           204..214
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          217..223
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          225..229
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           235..243
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          247..256
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   TURN            258..260
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          270..274
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          280..284
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           287..295
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          308..314
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           315..320
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          330..332
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           336..344
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          348..360
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          363..365
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   TURN            366..368
FT                   /evidence="ECO:0007829|PDB:6EGS"
FT   STRAND          369..371
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           373..376
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           378..388
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           390..392
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           393..399
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           401..403
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           412..420
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           426..432
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          445..452
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          455..458
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   TURN            463..465
FT                   /evidence="ECO:0007829|PDB:6EGS"
FT   STRAND          469..472
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           478..480
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          482..484
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          490..492
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          495..498
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          509..512
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           518..520
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          522..525
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   TURN            526..529
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          530..533
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          536..541
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           545..547
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          551..554
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   HELIX           559..561
FT                   /evidence="ECO:0007829|PDB:5AJO"
FT   STRAND          564..568
FT                   /evidence="ECO:0007829|PDB:5AJO"
SQ   SEQUENCE   571 AA;  64733 MW;  D9A0F5D17C55BAF2 CRC64;
     MRRRSRMLLC FAFLWVLGIA YYMYSGGGSA LAGGAGGGAG RKEDWNEIDP IKKKDLHHSN
     GEEKAQSMET LPPGKVRWPD FNQEAYVGGT MVRSGQDPYA RNKFNQVESD KLRMDRAIPD
     TRHDQCQRKQ WRVDLPATSV VITFHNEARS ALLRTVVSVL KKSPPHLIKE IILVDDYSND
     PEDGALLGKI EKVRVLRNDR REGLMRSRVR GADAAQAKVL TFLDSHCECN EHWLEPLLER
     VAEDRTRVVS PIIDVINMDN FQYVGASADL KGGFDWNLVF KWDYMTPEQR RSRQGNPVAP
     IKTPMIAGGL FVMDKFYFEE LGKYDMMMDV WGGENLEISF RVWQCGGSLE IIPCSRVGHV
     FRKQHPYTFP GGSGTVFARN TRRAAEVWMD EYKNFYYAAV PSARNVPYGN IQSRLELRKK
     LSCKPFKWYL ENVYPELRVP DHQDIAFGAL QQGTNCLDTL GHFADGVVGV YECHNAGGNQ
     EWALTKEKSV KHMDLCLTVV DRAPGSLIKL QGCRENDSRQ KWEQIEGNSK LRHVGSNLCL
     DSRTAKSGGL SVEVCGPALS QQWKFTLNLQ Q
//
